Procter & Gamble Health Limited PGHL NSEPHARMA
Company Overview
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Why Investors Should Care
Generates a return on equity of 62.3%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 76.8%.
Net profit has compounded at 19.3% per year over the last five years.
Maintains a net profit margin of 23.2%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹1,407.97 Cr (+24.7% YoY); net profit ₹326.91 Cr.
- Trailing 12 Months Year-on-year growth — revenue +24.7%, earnings +62.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.8%, profit CAGR 19.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.84% |
| 1 Year: | 24.66% |
Compounded Profit Growth
| 5 Years: | 19.30% |
| 1 Year: | 62.66% |
Stock Price Performance
| 1 Year: | -7.33% |
| 6 Months: | +17.03% |
| 3 Months: | -8.18% |
| 1 Month: | -5.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)35.17 · Neutral
P/E of 46.78 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 62.3%.
- Healthy ROCE of 76.8%.
- Excellent profit margin of 23.2%.
- Profit CAGR of 19.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PGHL Procter & Gamble Health Limited NSEPHARMA | 5,660.00 | 46.78 | ₹9,395.25 Cr | 1.48% | 76.81% | 62.32% | 8.84% | 19.30% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 310.99 Cr | 338.74 Cr | 324.92 Cr | 373.86 Cr | 370.45 Cr |
| Cost of Revenue | - | - | 98.72 Cr | 93.99 Cr | 68.40 Cr | 109.82 Cr | 92.87 Cr |
| Gross Profit | - | - | 212.27 Cr | 244.75 Cr | 256.52 Cr | 264.04 Cr | 277.58 Cr |
| Operating Expenses | - | - | 136.72 Cr | 159.85 Cr | 142.33 Cr | 159.48 Cr | 148.16 Cr |
| Operating Income | - | - | 75.55 Cr | 84.90 Cr | 114.19 Cr | 104.56 Cr | 129.42 Cr |
| EBITDA | - | - | 84.03 Cr | 94.37 Cr | 125.22 Cr | 114.82 Cr | 139.59 Cr |
| Interest Expense | - | - | 13.00 L | 12.00 L | 12.00 L | 10.00 L | 21.00 L |
| Pretax Income | - | - | 78.53 Cr | 88.81 Cr | 119.02 Cr | 108.82 Cr | 133.21 Cr |
| Tax Provision | - | - | 17.35 Cr | 22.63 Cr | 30.48 Cr | 31.23 Cr | 38.61 Cr |
| Net Income | - | - | 61.18 Cr | 66.18 Cr | 88.54 Cr | 77.59 Cr | 94.60 Cr |
| Diluted EPS | - | - | 36.86 | 39.87 | 53.54 | 46.74 | 56.99 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1,092.04 Cr | 1,205.86 Cr | 1,129.49 Cr | 1,407.97 Cr |
| Cost of Revenue | - | 367.11 Cr | 392.13 Cr | 359.49 Cr | 365.08 Cr |
| Gross Profit | - | 724.93 Cr | 813.73 Cr | 770.00 Cr | 1,042.89 Cr |
| Operating Expenses | - | 477.12 Cr | 517.88 Cr | 490.89 Cr | 609.82 Cr |
| Operating Income | - | 247.81 Cr | 295.85 Cr | 279.11 Cr | 433.07 Cr |
| EBITDA | - | 280.87 Cr | 343.07 Cr | 301.44 Cr | 474.00 Cr |
| Interest Expense | - | 42.00 L | 77.00 L | 72.00 L | 55.00 L |
| Pretax Income | - | 253.37 Cr | 314.20 Cr | 273.32 Cr | 449.86 Cr |
| Tax Provision | - | 60.85 Cr | 84.73 Cr | 72.34 Cr | 122.95 Cr |
| Net Income | - | 192.52 Cr | 229.47 Cr | 200.98 Cr | 326.91 Cr |
| Diluted EPS | 107.00 | 116.00 | 138.00 | 121.00 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 888.12 Cr | 1,101.19 Cr | 794.36 Cr | 841.35 Cr |
| Current Assets | - | 608.04 Cr | 796.10 Cr | 524.22 Cr | 556.26 Cr |
| Cash & Equivalents | - | 319.40 Cr | 435.05 Cr | 238.50 Cr | 177.24 Cr |
| Inventory | - | 115.21 Cr | 134.94 Cr | 109.11 Cr | 136.65 Cr |
| Receivables | - | 83.44 Cr | 115.71 Cr | 85.33 Cr | 164.26 Cr |
| Total Liabilities | - | 271.63 Cr | 350.30 Cr | 256.12 Cr | 316.80 Cr |
| Current Liabilities | - | 231.90 Cr | 303.90 Cr | 218.91 Cr | 254.93 Cr |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 2.83 Cr | 12.00 Cr | 9.56 Cr | 9.29 Cr |
| Total Equity | - | 616.49 Cr | 750.89 Cr | 538.24 Cr | 524.55 Cr |
| Shares Outstanding | - | 1.66 Cr | 1.66 Cr | 1.66 Cr | 1.66 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 169.52 Cr | 236.00 Cr | 228.29 Cr | 337.79 Cr |
| Investing Cash Flow | - | -25.54 Cr | -21.50 Cr | -6.87 Cr | 1.26 Cr |
| Financing Cash Flow | - | -288.63 Cr | -98.47 Cr | -418.11 Cr | -343.92 Cr |
| Capital Expenditure | - | -37.92 Cr | -42.48 Cr | -21.73 Cr | -15.51 Cr |
| Free Cash Flow | - | 131.60 Cr | 193.52 Cr | 206.56 Cr | 322.28 Cr |
| Net Change in Cash | - | -144.65 Cr | 116.03 Cr | -196.69 Cr | -4.87 Cr |
Ratios (Annual)
Figures in %.
| Metric | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 66.4% | 67.5% | 68.2% | 74.1% |
| Operating Margin % | - | 22.7% | 24.5% | 24.7% | 30.8% |
| Net Margin % | - | 17.6% | 19.0% | 17.8% | 23.2% |
| ROE % | - | 31.2% | 30.6% | 37.3% | 62.3% |
| ROCE % | - | 37.8% | 37.1% | 48.5% | 73.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PGHL
Read This Before Considering Procter & Gamble Health Limited (NSE:PGHL) For Its Upcoming ₹45.00 Dividend - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQLU93U2NxcWRSTE1iTnpteFR0MzgzSG9DeWdXYkRYQ2xhVmZqVGVuZHlQRzlSbHYzTEJNOFNxdG5nNXJrRzlrWVJSbGVONWVCTHhvVGZQcDJXSDZabWwtdzJQYXppSHhxZG1TcGRIMGlTOE1pSGdOMnVfSm1TODFHM3ROQkFBYjBpUHRRM0…
Procter & Gamble Health Share Price - Live NSE: PGHL Stock Price & Chart - Upstox
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTFB4V05VY3BvcTJma2cya0IyZGhKYVM4aE5qSnAxMjJ2Z0I0Z2JjSEw5eVpmMmlKTi05NUV0dlVQbW1maldfOVdLSGNCZmE0UjMwTUNqdnF0d0F4SlhyazhMR0k5aEluSGg5bjlOMWdpVQ?oc=5" target="_blank">Procter & Gamble …
Procter & Gamble Health (NSE:PGHL) Trades Ex-Dividend on Rs 45 Final Dividend - Kalkine India
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOenlDVXBUMzRuTUd0TUFMUGRwanpzeXZWeHl5OGloMGY0RXJPNVdwa3VYMnl5UW9HdmJEWFZ4d1BiZVVaR0hlVE9IZHE4ZFFvZHBvTGtmQTlVOURDa0tjWXNsYV95VVcySXdMQ0swcUVzaEpnLTR5MThfdHNzOXNKYjFJLVhHZk50N0RtNk…
Procter & Gamble Health (PGHL.NS) Holds Above Support as Defensive Demand Drives Mild Gains - Gap and Reverse - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNakhpcnlZZU9VY1NSZHRzem01RWsyNm1PdU5BNTk5QXpJX1lQQnVyckp5c0gzb2FhVDE4QmpaODd5cG8tQ3laRFNvNUM5SHVLYmlpOGtSTVE0cEJXZnZWYTR2TkFTRjJ4enVCR3J1UklWdkdQbnlGUzVLZGx4VVdBT0k0NVdadW1yNUFoaV…
Primega Group Holdings (PGHL) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE1FMFlRY3plV08wYzB5M2h3bXV3aTYxdjdSbURrcjh3ZWxDOUtmOTRGa1owRVdpdGs1azZ3Mk9fNlhWeUM1SlNZcWJBc1NsMEdBWnNN?oc=5" target="_blank">Primega Group Holdings (PGHL) Stock Price, News & Analy…
PGHL shares surges 3% on strong Q3 results, special dividend - BusinessLine
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOQ2Rmbno3SzBTemRaMUxQUXlUamhjcFZLQ2hPTDhuM0YyeGpCWjJUQXRrUm5Ud0kzZk5yS25BVWlMY3hRbDlGRzVFZmpLYmNiLV9JcjZzT19leXYxQkN4dmtTdzZObmswWThIdzFQdDM0Vy1sYnRNRXZEbFNoNWJqN0JMVThTSDE4ZzFGMm…
PGHL — Frequently Asked Questions
What is the current share price of Procter & Gamble Health Limited (PGHL)?
As of 2026-09-08 04:53 IST, Procter & Gamble Health Limited (PGHL) trades at ₹5,660.00 on NSE. Its 52-week range is ₹4,741.31 to ₹6,864.51.
What is the market capitalisation of PGHL?
Procter & Gamble Health Limited (PGHL) has a market capitalisation of ₹9,395.25 Cr on NSE.
What is the P/E ratio of PGHL?
PGHL trades at a trailing price-to-earnings (P/E) ratio of 46.78. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 19.44.
Does PGHL pay a dividend?
Procter & Gamble Health Limited (PGHL) currently offers a dividend yield of 1.48%.
What is the return on equity (ROE) of PGHL?
PGHL has a return on equity (ROE) of 62.32%. Its return on capital employed (ROCE) is 76.81%.
Is PGHL a good stock to buy?
This page provides a data-driven analysis of Procter & Gamble Health Limited (PGHL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.